ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1025

Dynamic Changes During SLE Flare Implicate Age-Associated B Cells and Altered T Follicular and Peripheral Helper Cell Responses in Disease Activity

Kieran Manion1, Zahi Touma 2, Dennisse Bonilla 2, Dafna Gladman 3, Murray Urowitz 2 and Joan Wither 4, 1Krembil Research Institute, Toronto, ON, Canada, 2University Health Network, University of Toronto, Toronto, ON, Canada, 3Krembil Research Institute, U of Toronto, Toronto, ON, Canada, 4University Health Network, Krembil Research Institute, Toronto, ON, Canada

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: autoimmune diseases and B cells, flare, SLE, T cells

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 11, 2019

Title: SLE – Etiology & Pathogenesis Poster I

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: SLE is a chronic autoimmune disorder in which periods of relative disease inactivity are punctuated by flares that present with increased inflammation and tissue damage. The current literature suggests that this enhanced disease activity is linked to immune cell subsets involved in ANA production, including T follicular (Tfh) and peripheral helper (Tph) cells, plasma cells, and age-associated B cells (ABCs); however, it is largely unknown how these and other immune subsets differ between flare and inactive disease, particularly in individual patients followed longitudinally.

Methods: 12 healthy controls (HC), 23 SLE patients with flare (Active) and 9 inactive SLE patients (Inactive) were recruited. All patients had a diagnosis of SLE based on the 1997 ACR criteria. Active patients had to be within 1 month of flare onset (defined as a clinical SLEDAI-2K≥0 requiring a change in therapy) and agree to follow-up assessments at 6 and 12 months. Inactive patients had to be inactive for ≥1 year (clinical SLEDAI-2K=0) and be on ≤10mg prednisone at recruitment. Peripheral blood mononuclear cells (PBMCs) were isolated over a Ficoll gradient within 3 hrs of collection, stained with fluorescent antibodies for immune cell subsets, and examined by flow cytometry. Statistical significance was determined using Kruskal-Wallis tests to compare HC, active and inactive SLE groups, Wilcoxon matched-pairs signed rank tests to compare baseline and follow-up visits, and Spearman tests for correlation.

Results: While active and inactive patients had increased proportions of Tph cells (CD4+PD1hiCXCR5–) compared to HC, only a small subset of patients in either group had elevated levels of plasma cells (CD19loCD27hiCD38+CD138+), plasmablasts (CD19loCD27hiCD38+CD138–) and activated memory Tfh cells (CD4+PD1hiCXCR5hi), with no differences between the two groups. In contrast, active patients had significantly more ABCs (CD19+CD21–CD11c+Tbet+) than inactive patients or HC and this correlated significantly with Tph cells (r=0.6909, p=0.0226). Interestingly, at their 6-month follow-up visit, active patients showed significant increases in Tfh and plasma cells, and trends to increased CD86+ B and Tph cells, despite improvements in their SLEDAI-2K. These findings suggest that activated T and B cells may be depleted from the blood during flares, possibly as a result of tissue recruitment. Notably, increases in activated memory Tfh cells post-flare were predominantly due to increases in the Tfh17 subset, while the Tfh2 subset was significantly decreased.

Conclusion: Our results show that while Tph cells and ABCs are elevated in active SLE, plasma cells and activated Tfh cells may be depleted from the peripheral blood during acute flare and return to the blood post-flare, reflecting recruitment to and subsequent release from tissues. These findings highlight the importance of longitudinal studies in individuals with active SLE.

Tbet+ age-associated B cells -ABCs; CD19+CD21-CD11c+Tbet+- are significantly elevated in SLE patients experiencing a flare as compared to healthy controls or inactive SLE patients.

Left Y-axis: Plasma cells -CD19loCD27hiCD38+CD138+- and T follicular helper cells -Tfh; CD4+PD1hiCXCR5hi- are significantly elevated in the blood of SLE patients at 6-months post-flare compared with baseline. Right Y-axis: Tfh17 cells -CD4+PD1hiCXCR5hiCXCR3-CCR6+- are significantly elevated in SLE patients 6-months post-flare compared with baseline, while Tfh2 cells -CD4+PD1hiCXCR5hiCXCR3-CCR6– show a significant decrease.


Disclosure: K. Manion, None; Z. Touma, Janssen Research & Development, LLC, 2, Janssen Scientific Affairs, LLC, 2; D. Bonilla, None; D. Gladman, None; M. Urowitz, Janssen Research & Development, LLC, 2, UCB Pharma, 9; J. Wither, None.

To cite this abstract in AMA style:

Manion K, Touma Z, Bonilla D, Gladman D, Urowitz M, Wither J. Dynamic Changes During SLE Flare Implicate Age-Associated B Cells and Altered T Follicular and Peripheral Helper Cell Responses in Disease Activity [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/dynamic-changes-during-sle-flare-implicate-age-associated-b-cells-and-altered-t-follicular-and-peripheral-helper-cell-responses-in-disease-activity/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/dynamic-changes-during-sle-flare-implicate-age-associated-b-cells-and-altered-t-follicular-and-peripheral-helper-cell-responses-in-disease-activity/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology